## Max Healthcare Institute Limited (MAXHEALTH) Investment Report - December 20, 2024

**1. Company Overview:**

Max Healthcare Institute Limited (MAXHEALTH) is a leading hospital company in India, operating within the Healthcare Services industry.  It was listed on the stock exchange on August 21, 2020.  MAXHEALTH holds a significant position in the Indian healthcare sector, known for its multi-specialty hospitals and advanced medical technologies.

**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | 1,163.05       | Closed at 1,165.2; Down from previous close.                       |
| Percentage Change (PChange) | -1.49%         | Significant negative daily change.                                   |
| Pre-Open Activity          | Mixed           | Some buy orders at higher prices, but overall limited pre-open activity.|
| Week High                   | 1,215.55       | Indicates recent price volatility.                                  |
| Week Low                    | 630.9          | Significant price drop within the week.                             |
| VWAP                        | 1,176.66       | Volume Weighted Average Price suggests a slightly higher average price.|
| Sector PE                   | 108.39         | High sector Price-to-Earnings ratio.                               |
| Symbol PE                   | 108.39         | High Price-to-Earnings ratio for MAXHEALTH.                         |
| Delivery Percentage         | 76.18%         | High delivery percentage suggests genuine buying interest.           |
| Market Depth                | Low             | Limited buy and sell orders in the order book.                     |


**3. Financial Performance:**

The following table summarizes the financial performance of MAXHEALTH over the past five quarters (all figures in INR):

| Quarter      | Revenue     | Expenditure | Profit After Tax | Diluted EPS |
|--------------|-------------|-------------|-----------------|-------------|
| Q3 FY25      | 81,962      | 50,147      | 23,130          | 2.38        |
| Q2 FY25      | 66,426      | 46,110      | 15,414          | 1.59        |
| Q1 FY25      | 74,788      | 45,726      | 24,177          | 2.49        |
| Q4 FY24      | 63,343      | 43,010      | 15,812          | 1.63        |
| Q3 FY24      | 64,491      | 43,488      | 16,131          | 1.66        |

**Analysis:** Revenue shows some fluctuation, but generally positive growth. Profit after tax and EPS also show some variability, but overall, the company demonstrates consistent profitability.  Further analysis of key financial ratios (e.g., ROE, ROA, Debt-to-Equity) is needed for a comprehensive assessment.


**4. Corporate Actions and Announcements:**

* **Dividends:**  Dividends of Rs 1.5 per share (ex-date August 23, 2024) and Re 1 per share (ex-date September 8, 2023) were declared.
* **Announcements:**  Numerous recent announcements relate to analyst meetings and general updates, suggesting active investor engagement.  No major negative news is apparent.

**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|--------------|---------------------------|--------|-----------------------------|-------|
| 30-Sep-2023  | 23.76%                     | 76.24% | 0.00%                        | 100.00%|
| 31-Dec-2023  | 23.75%                     | 76.25% | 0.00%                        | 100.00%|
| 31-Mar-2024  | 23.75%                     | 76.25% | 0.00%                        | 100.00%|
| 30-Jun-2024  | 23.74%                     | 76.26% | 0.00%                        | 100.00%|
| 30-Sep-2024  | 23.74%                     | 76.26% | 0.00%                        | 100.00%|

**Analysis:** Promoter holding remains relatively stable, indicating confidence in the company's prospects.


**6. Volatility and Risk Assessment:**

The stock exhibits significant volatility, as evidenced by the week's high and low prices.  The high annualized volatility (43.37%) from market depth data indicates substantial risk.  The risk-reward profile needs careful consideration.


**7. Advantages of Buying the Stock:**

* Consistent profitability and generally positive revenue growth.
* Strong sector positioning in a growing healthcare market.
* Relatively stable promoter holding.
* Regular dividend payouts.


**8. Disadvantages and Risks:**

* High volatility and risk.
* High PE ratio compared to the sector and market averages.
* Dependence on the Indian healthcare market and its regulatory environment.
* Fluctuations in financial performance.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Hold.** The recent price drop and high volatility make a short-term buy risky.  Holding is recommended until clearer price direction emerges.

* **Medium-term (3 to 12 months): Hold.**  The medium-term outlook depends on sustained financial performance and the overall market conditions.  Further monitoring is necessary.

* **Long-term (1 year and beyond): Hold/Consider Buy (with caution).**  The long-term prospects are tied to the growth of the Indian healthcare sector.  However, the high PE ratio and volatility warrant caution.  A buy decision should be made only after a thorough fundamental analysis and risk assessment.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Consistent profitability, but high PE ratio)
* Market Performance: 5/10 (High volatility, recent price drop)
* Volatility and Risk: 4/10 (High volatility, significant risk)
* Corporate Actions & Governance: 8/10 (Regular dividends, active investor communication)
* Shareholding Patterns: 7/10 (Stable promoter holding)

**Analysis Score (out of 10): 9/10**

* Completeness and Data Utilization: 10/10 (All data points were used)
* Accuracy and Clarity: 9/10 (Analysis is clear, but some ratios are missing)
* Professional Formatting: 10/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

MAXHEALTH presents a mixed investment picture. While the company demonstrates consistent profitability and operates in a promising sector, the high volatility and high PE ratio pose significant risks.  A "Hold" recommendation is given for the short and medium term, allowing for further observation of price action and financial performance.  A cautious "Hold/Consider Buy" is suggested for the long term, contingent upon a more in-depth fundamental analysis and a more favorable risk-reward profile.  Investors should carefully consider their risk tolerance before making any investment decisions.  Further analysis including key financial ratios (ROE, ROA, Debt-to-Equity ratio, etc.) is recommended for a more comprehensive evaluation.
